Medical device company Mauna Kea Technologies (Paris:MKEA) (OTCQX:MKEAY) (Euronext:MKEA) disclosed on Wednesday that it expects preliminary sales in a range of EUR2.2m to EUR2.3m for the Q4 2020.
This marks a rise of approximately 30% to 36% year-over-year.
In the Q4 2020, the company anticipates US sales to grow approximately 34% to 38% year-over-year and Rest of World (ROW) sales are expected to escalate by approximately 26% to 33% year-over-year.
For the Q4 2020, the consumables sales are expected to decline approximately 9% to 14% year-over-year; Systems sales are expected to shoot up by approximately 177% to 185% year-over-year; Services sales are expected to decrease approximately 9% to 13% year-over-year.
Halma acquires Rovers Medical Devices
boston Scientific granted FDA approval for AGENT Drug-Coated Balloon
Enable Injections names new chief operating officer
BridgeBio Pharma and Kyowa Kirin partner on infigratinib for skeletal dysplasias in Japan
Redwood Scientific signs agreement with Jeeva Clinical Trials
Tissue Regenix ships first allograft products in the EU post-HPRA approval
Kromek secures GBP1.3m grant for AI-powered radiation sensor project